Brind.
  1. FDA approved the Farapulse system use, and the company anticipates further regulatory approvals in Europe and Japan. Analysts are bullish on the stock.

FDA granted expanded labeling approval for Boston Scientific's PFA System, with the company anticipating further regulatory approvals in Japan and China.

1 report, 0 independent Updated Jul 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

FDA granted expanded labeling approval for Boston Scientific's PFA System, with the company anticipating further regulatory approvals in Japan and China.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Unknown outlet